secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058654
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aficamten Phase 3 SEQUOIA-HCM meets primary endpoint: pVO2 improved 1.8 vs 0.0 mL/kg/min (p=0.000002)
--------------------------------------------------------------------------------

- All 10 prespecified secondary endpoints met, including KCCQ-CSS (+7 points, p<0.0001) and NYHA class improvement (34%, p<0.0001).
- Treatment reduced days eligible for septal reduction therapy by 78 days vs placebo (p<0.0001).
- No treatment interruptions due to low LVEF; serious adverse events 5.6% aficamten vs 9.3% placebo.
- Results presented at ESC Heart Failure 2024 and published in New England Journal of Medicine.
- Composite responder endpoint achieved by 42% aficamten vs 14% placebo (p<0.0001).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024058654/0000950170-24-058654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024058654/cytk-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer